Search
Desfesoterodine
go.drugbank.com/drugs/DB15578InvestigationalDesfesoterodine is a metabolite of [tolterodine].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesSynonyms: 5-HydroxymethyltolterodineCryptotanshinone
go.drugbank.com/drugs/DB15579ExperimentalSynonyms: Tanshinone CCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsChrysin
go.drugbank.com/drugs/DB15581InvestigationalCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingPatulin
go.drugbank.com/drugs/DB15586InvestigationalCategories: Heterocyclic Compounds, 1-Ring, Compounds used in a research, industrial, or household settingAntimony potassium tartrate
go.drugbank.com/drugs/DB15587ExperimentalAntimony potassium tartrate is a schistosomicide possibly useful against other parasites. It has irritant emetic properties and may cause lethal cardiac toxicity among other adverse effects.
Synonyms: Potassium antimonyl D-tartrateBrilliant blue G
go.drugbank.com/drugs/DB15594ApprovedBrilliant blue G, like its name, imparts a vibrant blue color, facilitating identification of the ILM. It was approved by the FDA for ophthalmic use on December 20, 2019.[L10830] … Brilliant Blue G is used in an ophthalmic solution for staining the internal limiting membrane (ILM) of the eye during ophthalmic procedures.
Categories: Compounds used in a research, industrial, or household settingSynonyms: Brilliant blue G, Coomassie Brilliant Blue GJPC-3210
go.drugbank.com/drugs/DB15609ExperimentalJPC-3210 is a potent antimalarial agent. … antimalarial activity against multidrug-resistant _Plasmodium falciparum_ lines, low cytotoxicity, potent in vivo efficacy against murine malaria, and favourable preclinical pharmacokinetics including a
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP3A InhibitorsPrevitamin D(3)
go.drugbank.com/drugs/DB15614InvestigationalCategories: Vitamin D and AnaloguesSynonyms: Previtamin D(3), Previtamin DREC-994
go.drugbank.com/drugs/DB15616InvestigationalREC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).